Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab

7 Apr 2020

Abstract excerpt

The global occurrence of inflammatory bowel diseases, including Crohn’s disease (CD), is rising, with prevalence of 0.5% to 1.0% reported in Europe and North America.1 Biological therapies are a mainstay of patient management, with monoclonal antibodies against tumor necrosis factor (TNF), infliximab and adalimumab, widely used as first-line agents. Highly effective in some individuals, continued use of these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunodeficiency and Autoimmune Disorders
Share to Inflammatory Bowel Disease
Share to Systemic Lupus Erythematosus Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32275970
DOI: 10.1053/j.gastro.2020.03.073

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabPMID 32275970Read ↗

Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD PatientsSemantic proximity Read ↗

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity Read ↗

The genetics of IBD : from susceptibility to drug response and patient outcomeSemantic proximity Read ↗

Identification of HLA-DRB1 association to adalimumab immunogenicity.Semantic proximity Read ↗

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.Semantic proximity Read ↗

Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.Semantic proximity Read ↗

Revisiting HLA-DQA1*05 in Asian inflammatory bowel disease cohorts: Ethnic variations in genetic susceptibility to immunogenicity.Semantic proximity Read ↗

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.Semantic proximity Read ↗

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studySemantic proximity Read ↗

Treatment of Chronic Inflammatory Diseases – The Potential of PharmacogeneticsSemantic proximity Read ↗

Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.